OSEL Devices Q4 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹597 Cr
- P/E
- 20.42
- ROE
- 19.56%
- PEG
- 0.25
- Price to sales
- 2.05
- Debt to equity
- 0.49
- 52W high / low
- ₹804 / ₹332
- Sales growth (5Y)
- 38.54%
- EBITDA margin
- 18.23%
- Net profit margin
- 9.99%
- Promoter holding
- 64.84%
- Sales (last year)
- ₹293 Cr
Founded in 2006, Osel Devices Limited manufactures LED display systems and hearing aids.[1]
Guidance scorecard · Q4 FY26 call
What OSEL Devices Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ4 FY26 call
40%+- OSEL expects continued positive growth in sales and revenue for the next few years, maintaining or exceeding recent growth rates.
- Mobile sales (feature phones) are stable at 60,000-70,000 units monthly, with volumes expected to rise, especially during festivals.
- FY26 mobile sales amounted to around INR55 crores in H2, with an overall FY26 revenue close to INR300 crores; FY27 target is to surpass INR500 crores.
- Smartphone manufacturing recently started and is expanding, branded under Philips, with expectations of higher contributions to the top line.
- Export sales target is INR50 crores for the current year, up from INR23 crores last year.
- The manufacturing hub at JNPA (Navi Mumbai) will enhance export capabilities and revenues.
2 more points from OSEL Devices Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what OSEL Devices Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- OSEL Devices has planned a capital expenditure project for setting up a manufacturing hub at JNPA (Jawaharlal Nehru Port Authority) in Navi Mumbai.
- The facility will operate as a Special Economic Zone (SEZ) focusing mainly on LED business, targeting international markets like North America, the Middle East, and Africa.
- This hub will offer tax advantages, no import duties, and logistic benefits due to its strategic port location.
- The company has recently received the Letter of Intent (LOI) for this project and is currently working on project planning.
- Exact capex amount and timelines will be clarified once the project plan is finalized.
2 more points from OSEL Devices Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what OSEL Devices Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- The company has a sizable ongoing engagement in the defense segment with clients such as IMA Military Academy, Naval Academy, Air Force, DRDO, and ISRO.
- Growth in defense orders is expected with the onboarding of Captain Vivek, who is actively engaging with defense clients.
- The company received an LOI for the JNPA manufacturing hub project and is working on its implementation, which will add to order inflows.
- They have ongoing OEM LED manufacturing orders for big brands.
- Export orders are growing, with INR23 crores done last year and a target of INR50 crores this year.
2 more points from OSEL Devices Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- 1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | OSEL DevicesThis stock | 40%+ | Flat | ₹627 Cr | 21.4 |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track OSEL Devices Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingOSEL Devices Ltd announcements
All announcements →- Fundraise / allotmentNotableOSEL Devices appoints Kapil Kohli as Strategic Consultant and approves warrant issue
- Fundraise / allotmentNotableOSEL Devices Ltd appoints Strategic Consultant and approves interim dividend, warrants issue
- Fundraise / allotmentNotableOSEL Devices announces interim dividend, warrant issue, and consultant appointment
Financials of OSEL Devices Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
OSEL Devices Ltd
Shareholding breakup across reporting periods.
| Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters + | 71.53% | 71.53% | 71.53% | 65.21% | 65.21% | 64.84% | 64.84% |
| FIIs + | 4.13% | 1.83% | 1.46% | 0.59% | 0.15% | 0.18% | 0.12% |
| DIIs + | 5.88% | 5.38% | 5.01% | 3.89% | 3.56% | 3.56% | 3.32% |
| Public + | 18.46% | 21.26% | 22.00% | 30.31% | 31.09% | 31.42% | 31.72% |
| No. of Shareholders | 1,525 | 1,897 | 2,104 | 1,865 | 2,777 | 3,241 | 3,541 |
Financials of OSEL Devices Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of OSEL Devices Ltd
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 57 | 65 | 82 | 132 | 186 | 293 |
| Expenses + | 55 | 61 | 73 | 110 | 153 | 239 |
| Operating Profit | 3 | 4 | 9 | 22 | 33 | 53 |
| OPM % | 4.9% | 7% | 11% | 17% | 18% | 18% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 0 | 1 | 1 | 3 | 3 | 10 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 3 | 7 | 19 | 29 | 44 |
| Tax % | 33% | 29% | 33% | 32% | 31% | 34% |
| Net Profit + | 1 | 2 | 5 | 13 | 20 | 29 |
| EPS in Rs | 1.62 | 1.84 | 4.05 | 10.99 | 12.43 | 16.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of OSEL Devices Ltd
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 2 | 2 | 12 | 16 | 18 |
| Reserves | 4 | 6 | 10 | 14 | 92 | 173 |
| Borrowings + | 10 | 9 | 18 | 25 | 50 | 94 |
| Other Liabilities + | 8 | 17 | 19 | 48 | 40 | 52 |
| Total Liabilities | 23 | 33 | 49 | 99 | 198 | 338 |
| Fixed Assets + | 6 | 5 | 7 | 18 | 17 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 48 |
| Other Assets + | 17 | 28 | 42 | 80 | 180 | 261 |
| Total Assets | 23 | 33 | 49 | 99 | 198 | 338 |
Financials of OSEL Devices Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -3 | 3 | -11 | 13 | -69 | -20 |
| Cash from Investing Activity + | 0 | 0 | -2 | -13 | -11 | -76 |
| Cash from Financing Activity + | 5 | -2 | 8 | 4 | 83 | 89 |
| Net Cash Flow | 2 | 1 | -4 | 4 | 4 | -7 |
| Free Cash Flow | -3 | 2 | -12 | 0 | -69 | -33 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -106% | 72% | -113% | 67% | -188% | -22% |
Financials of OSEL Devices Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 45 | 63 | 57 | 73 | 128 | 134 |
| Inventory Days | 28 | 63 | 94 | 91 | 104 | 94 |
| Days Payable | 37 | 94 | 84 | 130 | 77 | 56 |
| Cash Conversion Cycle | 36 | 33 | 67 | 35 | 156 | 172 |
| Working Capital Days | -12 | -7 | 27 | 38 | 139 | 108 |
| ROCE % | 26% | 35% | 54% | 31% | 24% |
Guidance history
How OSEL Devices Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 40%+ | Flat | Planned | — | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | Rising |
| Q4 FY25 call → | 20–40% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
4 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −45.4% | 8% |
| Last 6 months | −43.8% | 2% |
| Last 3 months | −18.8% | 25% |
The price is 58.3% below its all-time high of ₹803.6 (20 Nov 2025). Stocks more than 20% below their peak have their score halved, so 9 became 4.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For OSEL Devices Ltd: 0.4 × 8 + 0.4 × 2 + 0.2 × 25 = 9, halved to 4 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What OSEL Devices Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec